- Home
- BCAB vs NYC Comparison
BCAB vs NYC Comparison
Compare BCAB & NYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- NYC
- Stock Information
- Founded
- BCAB 2007
- NYC 2013
- Country
- BCAB United States
- NYC United States
- Employees
- BCAB N/A
- NYC N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- NYC Real Estate
- Sector
- BCAB Health Care
- NYC Finance
- Exchange
- BCAB Nasdaq
- NYC Nasdaq
- Market Cap
- BCAB 31.5M
- NYC 25.5M
- IPO Year
- BCAB 2020
- NYC N/A
- Fundamental
- Price
- BCAB $0.72
- NYC $9.60
- Analyst Decision
- BCAB Hold
- NYC
- Analyst Count
- BCAB 3
- NYC 0
- Target Price
- BCAB $1.00
- NYC N/A
- AVG Volume (30 Days)
- BCAB 1.1M
- NYC 3.4K
- Earning Date
- BCAB 11-06-2025
- NYC 11-11-2025
- Dividend Yield
- BCAB N/A
- NYC N/A
- EPS Growth
- BCAB N/A
- NYC N/A
- EPS
- BCAB N/A
- NYC N/A
- Revenue
- BCAB $11,000,000.00
- NYC $54,865,000.00
- Revenue This Year
- BCAB N/A
- NYC $8.40
- Revenue Next Year
- BCAB N/A
- NYC $1.62
- P/E Ratio
- BCAB N/A
- NYC N/A
- Revenue Growth
- BCAB N/A
- NYC N/A
- 52 Week Low
- BCAB $0.24
- NYC $7.89
- 52 Week High
- BCAB $2.53
- NYC $16.30
- Technical
- Relative Strength Index (RSI)
- BCAB 56.79
- NYC 36.10
- Support Level
- BCAB N/A
- NYC $9.11
- Resistance Level
- BCAB $0.84
- NYC $10.50
- Average True Range (ATR)
- BCAB 0.07
- NYC 0.77
- MACD
- BCAB -0.00
- NYC -0.05
- Stochastic Oscillator
- BCAB 85.96
- NYC 22.98
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.